Digital health pioneer BlinkLab (ASX:BB1) secured $17.5 million through an oversubscribed share placement, marking a definitive leap forward in the commercialisation of its smartphone-based neurodevelopmental diagnostic platforms.
The capital raise, priced at $0.65 per share, issued nearly 27 million new ordinary shares and saw backing from company directors, who committed an additional $200,000.
The fresh injection of capital is primarily earmarked for the completion of pivotal FDA 510(k) clearance trials for the company’s flagship autism diagnostic aid, Dx1.
With the first participant already enrolled in a multi-centre, double-blinded study led by IQVIA-MCRA, BlinkLab is targeting a formal US regulatory submission by the end of 2026.
Simultaneously, the funds will accelerate CE marking and EU MDR processes to facilitate a European rollout.
Beyond its autism-focused efforts, BlinkLab is aggressively expanding its clinical pipeline into the US ADHD market.
The proceeds will fund the launch of the Dx2 platform trials, aiming for a secondary FDA 510(k) pathway.
The technological expansion is bolstered by recent real-world validation in Morocco, where the government has selected Dx1 for a nationwide, state-funded autism screening initiative for toddlers.
Commencing this month, the Moroccan programme provides a unique, large-scale implementation environment that complements the company's rigorous clinical trials.
At the time of reporting, BlinkLab's share price was $0.75.